The pharma-biotech executive jumps show no sign of abating as a former Pfizer vet joins the ranks of startup Outpost Medicine as its R&D trials lead.
Ian Mills, M.D., becomes its new chief medical officer, coming from his role as head of clinical development at Mitsubishi Tanabe Pharma Europe; before this, he was a long-serving Pfizer vet serving across several research posts, with a focus on urology.
Outpost, with bases in Indianapolis and London, launched just last year and has since raised $61 million in a series A from the likes of Frazier Healthcare Partners, Adams Street Partners, Novo Holdings, Vivo Capital and Takeda Venture.
When it launched, Takeda gave out an exclusive license to the early-stage biotech for a clinical-stage product candidate in testing for stress urinary incontinence.
“Ian will be an outstanding addition to our leadership team, and we are very pleased to welcome him to Outpost,” said Scott Byrd, CEO of Outpost and formerly of Acacia Pharma and Lilly, in a release. “His extensive global drug development experience, including successfully guiding two pharmaceutical products to FDA approval for urology indications, will be pivotal to building our capabilities and leading the development of our lead product candidate, OP-687, for the treatment of overactive bladder and irritable bowel syndrome.”
By Ben Adams
Source: Fierce Biotech
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
